Navigation Links
Chilean President's Cousin Successfully Tests Allergy 'Knockout' Technique on Mice

A doctoral student at the Hebrew University of Jerusalem School of Pharmacy, who is the first cousin of Chilean President Michelle Bachelet, has been conferred a prestigious research prize for developing a new approach that may help eliminate allergies like the common cold and asthma.

Chilean-born Ido Bachelet has been honoured with the Barenholz Prize, which is named for the donor of the prize money and noted researcher Prof. Yehezkel Barenholz of the Hebrew University-Hadassah Medical School, in recognition of his contribution in the development of the "knockout technique" in special "antibody nose drops" against allergies that has been tested successfully on lab mice.

Bachelet shared the award with another researcher during the Hebrew University Borad of Governors 70th meeting in Jerusalem recently. The award is given for "creativity and originality in applied research".

The Ph.D student, who is working under the supervision of Prof. Francesca Levi-Schaffer, focused his research on mechanisms that regulate the function of mast cells, the "villains" in triggering allergic reactions.

Acute symptoms like stuffy nose, rash and airway constriction, and lethal shock known from food or venom allergies occur when, as a result of exposure to allergens, mast cells react violently and release an enormous array of pro-inflammatory substances, of which histamine is a well-known example. They later on attract inflammatory cells that will maintain the response, which often persists as a chronic disease.

Bachelet's study has led to the identification of a receptor protein on mast cells, termed CD300a, which has a prominent negative effect on mast cell activity, virtually shutting down the cell from unleashing allergic responses.

The identified protein receptor is widely found throughout the immune system and, just like steroids, targeting it could result in undesired, overall immune suppressi on with serious consequences.

With a view to overcome this problem, Bachelet and his research colleague Ariel Munitz have designed a small, synthetic, antibody fragment that has the unusual ability of recognizing two targets simultaneously-the receptor CD300a and a mast cell-specific marker. This makes the antibody targets CD300a only on the surface of mast cells, avoiding suppression of other immune cells.

During the study, this antibody potently eliminated four different types of allergic diseases in mice. The researchers also noted that upon administration of the antibody in nose drops, mice suffering from sever chronic asthma completely reverted to normal in less than two months.

Termed RECEPTRA, the pioneering project presents a novel therapeutic strategy for acute and chronic allergic diseases, and is currently being licensed through Yissum, the Hebrew University's technology transfer company, to pharmaceutical companies for further development and eventual clinical trials.

Bachelet predicts that with further development, his technology may become the first line of allergy therapy in the near future.


'"/>




Related medicine news :

1. Former Chilean Dictator Hospitalised After Heart Attack
2. Former Chilean Dictator Recovering
3. Chicken Dishes Were Off The Menu At Pakistan Presidents House
4. Reserved category doctors seek Presidents intervention
5. US Senate Approves Embryo-research Plan Despite Presidents Refusal
6. Cipro Has Cheaper Cousins to Treat Anthrax
7. Fruitfly My Distant Cousin
8. Cousins Recovering from His Substance Abuse Problem
9. Cousins Recovering from His Substance Abuse Problem
10. French Doctors Successfully Separate Twins Joined At Spine
11. Alzheimer’s disease trial With EVT 101 For Successfully Complete
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... Calif. (PRWEB) , ... April 29, 2016 , ... Our ... An effective way to confront and deal with these stressors is to adopt a ... to be good for you. Risa Groux, a certified Holistic Nutritionist and the creator ...
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie Siegel, ... "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live on ... Dr. Bernie Siegel, author of a plethora of essential books-to-read for physicians ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016  In the next ten years, ... from systems dependent on CRTs monitors to those reliant ... CRT Medical monitors and will automatically sync to ... of foreseeable benefits to this technological advancement, it ... have to be replaced in order to be ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
(Date:4/29/2016)... 2016 Acquisition Expands the ... Development Capabilities in North America ... Indegene ( http://www.indegene.com ), a ... of Skura Corporation,s life science business. Skura,s SFX ... enablement technology for life science organizations and delivers ...
Breaking Medicine Technology: